THU-180-Treatment of genotype 3 HCV infection in the large real-life “Navigatore Lombardia” multicentre cohort: Results from three different regimens

Soria, Alessandro; Lapadula, Giuseppe; Colella, Elisa; Gambaro, Alessandra; Spolti, Anna; Bottalico, Nunzia; Pasulo, L.; Carderi, I.; Lazzaroni, Sergio; Boldizzoni, Roberto; Scabeni, Luciana; Poggio, P. Del; Mels, Guido Colloredo; Marco, Mariella Di; Colombo, Alberto; Spinelli, Ombretta; Pigozzi, Marie Graciella; Graffeo, M; Spinetti, Angiola; Carriero, Canio; Menzaghi, Barbara; Terreni, N.; Brambilla, Paola; Pan, Angelo; Bella, Daniele; Liani, C.; Polo, Silvia; Aimo, Gianpiero; Bhoori, Sherrie; Bonfanti, Paolo; Molteni, Chiara; Gatti, Fábio; Viganó, Paolo; Dionigi, Elena; Centenaro, Riccardo; Vinci, M.; Puoti, Massimo; Borghi, Marta; D’Ambrosio, Roberta; Degasperi, Elisabetta; Soffredini, R.; Valenti, L.; Gulminetti, Roberto; Lombardi, Andrea; Schiavini, Monica; Landonio, Simona; Rizzardini, Giuliano; Capretti, A.; Rumi, Maria Grazia; Viganò, Mauro; Giorgini, Alessia; Merlini, Esther; Bona, Anna De; Monforte, Antonella d’Arminio; Uberti‐Foppa, Caterina; Hasson, Hamid; Salpietro, Stefania; Grossi, Paolo; Aghemo, Alessio; Gritti, Sara; Noventa, Franco; Lampertico, Pietro; Fagiuoli, S.

doi:10.1016/s0618-8278(19)30455-4

Journal of Hepatology

2019

DOI: 10.1016/s0618-8278(19)30455-4

|View full text |Cite

THU-180-Treatment of genotype 3 HCV infection in the large real-life “Navigatore Lombardia” multicentre cohort: Results from three different regimens

Alessandro Soria¹,

Giuseppe Lapadula²,

Elisa Colella³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(17)(18)(19)(20)(21)(22)(23)). Model inputs for process time based on the CP are shown in Supplemental Table EIV.…”

mentioning

confidence: 99%

Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

Fagiuoli

Ruggeri

Aragão

et al. 2021

Grhta

Self Cite

View full text Add to dashboard Cite

Introduction: The current paradigm (CP) of hepatitis C virus (HCV) diagnosis and treatment in Italy’s National Health Service system has numerous steps. The European Association for the Study of the Liver recommends initiation of a pan-genotypic direct-acting antiviral regimen after a simple diagnostic process. The present study estimated the efficiency gains resulting from two simplified pathways from diagnosis to treatment of chronic hepatitis C patients in Italy over the next 5 years from a societal perspective. Methods: The CP, a New Paradigm 1 (NP1), and a New Paradigm 2 (NP2) were evaluated in a Markov model. The NP1 model simplifies monitoring and laboratory test requirements in the diagnosis and treatment phases. The NP2 model also eliminates the primary care referral requirement. Results: Treatment process time for non-cirrhotic patients was 48, 43, and 25 weeks in the CP, NP1, and NP2, respectively, and in cirrhotic patients was 49, 46, and 37 weeks. Under the CP, 19% of patients/year would be lost to follow-up, which decreases by 11% in NP1 and 100% in NP2. Compared with the CP, implementation of NP1 at 5 years would reduce compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liverrelated deaths by 12.6%, 12.4%, 8.1%, and 8.8%, respectively; these cases would be reduced by 94.0%, 93.8%, 61.0%, and 58.4% in NP2. Total 5-year costs with the CP, NP1, and NP2 are estimated at 135.6€ million, 110.5€ million, and 80.5€ million, respectively. Conclusions: Simplification of HCV diagnosis and monitoring requirements would allow Italy to move closer to international guidelines with significant health benefits and economic gains.

show abstract

“…(17)(18)(19)(20)(21)(22)(23)). Model inputs for process time based on the CP are shown in Supplemental Table EIV.…”

mentioning

confidence: 99%

Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

Fagiuoli

Ruggeri

Aragão

et al. 2021

Grhta

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

THU-180-Treatment of genotype 3 HCV infection in the large real-life “Navigatore Lombardia” multicentre cohort: Results from three different regimens

Cited by 1 publication

References 0 publications

Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

Contact Info

Product

Resources

About